Download PDF
Fortschr Neurol Psychiatr 2014; 82(4): 228-238
DOI: 10.1055/s-0034-1365945
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

MAO-Hemmer als Behandlungsoption der therapieresistenten Depression

Anwendung, Wirksamkeit und BesonderheitenMAO-Inhibitors – A Treatment Option for Treatment Resistant DepressionApplication, Efficacy and Characteristics
S. Köhler
1   Klinik für Psychiatrie und Psychotherapie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin
,
L. A. Stöver
1   Klinik für Psychiatrie und Psychotherapie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin
,
T. Bschor
2   Abteilung für Psychiatrie der Schlosspark-Klinik Berlin und Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
› Author Affiliations
Further Information

Publication History

Publication Date:
07 April 2014 (online)

Also available at
    Permissions and Reprints

Lernziele

Ziel des vorliegenden Artikels ist es, die Bedeutung der Monoaminooxidase-Hemmer für die Behandlung der therapieresistenten Depression darzustellen. Weiterhin werden der Wirkmechanismus und die daraus resultierenden Besonderheiten erläutert. Insbesondere die Ernährungshinweise, die spezifischen Nebenwirkungen sowie Medikamenteninteraktionen werden aufgezeigt und praktische Hinweise für den Behandlungsalltag vermittelt.

 

  • Literatur

  • 1 Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Jama 2003; 289: 3095-3105
    CrossrefPubMedGoogle Scholar
  • 2 Bschor T. Therapy-resistant depression. Expert Rev Neurother 2010; 10: 77-86
    CrossrefPubMedGoogle Scholar
  • 3 Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917
    CrossrefPubMedGoogle Scholar
  • 4 Adli M, Pilhatsch M, Bauer M et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatry 2008; 41: 252-257
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Lewitzka U. Irreversible MAO-Hemmer. In: Bschor T, Hrsg Behandlungsmanual therapieresistente Depression Pharmakotherapie – somatische Therapieverfahren – Psychotherapie. Stuttgart: Kohlhammer; 2008: 102-113
    Google Scholar
  • 6 Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem 2004; 11: 2033-2043
    CrossrefPubMedGoogle Scholar
  • 7 Crane GE. The psychiatric side-effects of iproniazid. Am J Psychiatry 1956; 112: 494-501
    CrossrefPubMedGoogle Scholar
  • 8 Laux G, Becker T, Müller U. Monoaminoxidasehemmer. In: Riederer P, Laux G, Pöldinger W, Hrsg Neuro-Psychopharmaka – Ein Therapiehandbuch Band 3 Wien. New York: Springer; 2002: 489-507
    CrossrefGoogle Scholar
  • 9 Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008; 13: 855-870
    PubMedGoogle Scholar
  • 10 Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12: 185-219
    CrossrefPubMedGoogle Scholar
  • 11 Gordon MN, Muller CD, Sherman KA et al. Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacol Biochem Behav 1999; 63: 501-506
    CrossrefPubMedGoogle Scholar
  • 12 Baker GB, Coutts RT, McKenna KF et al. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatry Neurosci 1992; 17: 206-214
    PubMedGoogle Scholar
  • 13 Laux G, Volz HP, Möller HJ. Newer and older monoamine oxidase inhibitors. A comparative profile. CNS Drugs 1995; 3: 145-158
    CrossrefPubMedGoogle Scholar
  • 14 Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999; 20: 226-247
    CrossrefPubMedGoogle Scholar
  • 15 Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001; 57: 161-178
    CrossrefPubMedGoogle Scholar
  • 16 Himmelhoch JM, Thase ME, Mallinger AG et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-916
    CrossrefPubMedGoogle Scholar
  • 17 Thase ME, Frank E, Mallinger AG et al. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992; 53: 5-11
    PubMedGoogle Scholar
  • 18 Thase ME, Mallinger AG, McKnight D et al. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149: 195-198
    CrossrefPubMedGoogle Scholar
  • 19 Nolen WA. Tranylcypromine in depression resistant to cyclic antidepressions. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 155-158
    CrossrefPubMedGoogle Scholar
  • 20 Volz HP, Faltus F, Magyar I et al. Brofaromine in treatment-resistant depressed patients – a comparative trial versus tranylcypromine. J Affect Disord 1994; 30: 209-217
    CrossrefPubMedGoogle Scholar
  • 21 McGrath PJ, Stewart JW, Fava M et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006; 163: 1531-1541 quiz 1666
    CrossrefPubMedGoogle Scholar
  • 22 Rossel L, Moll E. Moclobemide versus tranylcypromine in the treatment of depression. Acta Psychiatr Scand Suppl 1990; 360: 61-62
    PubMedGoogle Scholar
  • 23 Heinze G, Rossel L, Gabelic I et al. Double-blind comparison of moclobemide and tranylcypromine in depression. Pharmacopsychiatry 1993; 26: 240-245
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Rapaport MH, Thase ME. Translating the evidence on atypical depression into clinical practice. J Clin Psychiatry 2007; 68: e11
    CrossrefPubMedGoogle Scholar
  • 25 McGrath PJ, Stewart JW, Harrison W et al. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 1987; 23: 169-172
    PubMedGoogle Scholar
  • 26 Liebowitz MR, Quitkin FM, Stewart JW et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988; 45: 129-137
    CrossrefPubMedGoogle Scholar
  • 27 Quitkin FM. Depression With Atypical Features: Diagnostic Validity, Prevalence, and Treatment. Prim Care Companion J Clin Psychiatry 2002; 4: 94-99
    CrossrefPubMedGoogle Scholar
  • 28 McGrath PJ, Stewart JW, Nunes EV et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993; 150: 118-123
    CrossrefPubMedGoogle Scholar
  • 29 Laux G, Ulrich S. Tranylcypromin. Psychopharmakotherapie 2006; 13: 130-140
    PubMedGoogle Scholar
  • 30 Adli M, Baethge C, Heinz A et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387-400
    CrossrefPubMedGoogle Scholar
  • 31 Feighner JP, Herbstein J, Damlouji N. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 1985; 46: 206-209
    PubMedGoogle Scholar
  • 32 Flockhart DA. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. J Clin Psychiatry 2012; (Suppl. 01) 73
    PubMedGoogle Scholar
  • 33 Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract 2004; 10: 239-248
    CrossrefPubMedGoogle Scholar
  • 34 el-Ganzouri AR, Ivankovich AD, Braverman B et al. Monoamine oxidase inhibitors: should they be discontinued preoperatively?. Anesth Analg 1985; 64: 592-596
    PubMedGoogle Scholar
  • 35 Naguib M, Koorn R. Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management. CNS Drugs 2002; 16: 229-247
    CrossrefPubMedGoogle Scholar
  • 36 Briggs NC, Jefferson JW, Koenecke FH. Tranylcypromine addiction: a case report and review. J Clin Psychiatry 1990; 51: 426-429
    PubMedGoogle Scholar
  • 37 Walker SE, Shulman KI, Tailor SA et al. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol 1996; 16: 383-388
    CrossrefPubMedGoogle Scholar
  • 38 Köberle U, Bschor T. Dysarthrie als serotonerge Nebenwirkung durch Interaktion zwischen Duloxetin und Tramadol. Psychopharmakotherapie 2007; 14: 82-84
    PubMedGoogle Scholar
  • 39 Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42: 1578-1583
    CrossrefPubMedGoogle Scholar
  • 40 DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) für die Leitliniengruppe Unipolare Depression (2009) S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression, 1. Auflage 2009. DGPPN, ÄZQ, AWMF – Berlin, Düsseldorf 2009. Internet: www.dgppn.de, www.versorgungsleitlinien.de, www.awmf-leitlinien.de
    PubMed
  • 41 Vandenberg CM. MAOIs and transdermal delivery. J Clin Psychiatry 2012; 73: e28
    CrossrefPubMedGoogle Scholar
  • 42 Bschor T. Monoaminooxidase und -Hemmer. In: Affektive Störungen XXS pocket. Grünwald: Börm Bruckmeier Verlag; ; 2009; 66
    Google Scholar
  • 43 Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol 2011; 31: 66-74
    CrossrefPubMedGoogle Scholar
  • 44 Grossman E, Messerli FH, Grodzicki T et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?. JAMA 1996; 276: 1328-1331
    CrossrefPubMedGoogle Scholar